Answers are grounded in this paper and cite their sources.
Taxane-based chemotherapy is a standard treatment for breast cancer but is frequently associated with moderate-to-severe chemotherapy-induced peripheral neuropathy (CIPN), which may necessitate dose reductions or treatment discontinuation. Given the limited efficacy of available interventions, early identification of patients at high risk of CIPN is essential. A total of 355 patients with breast cancer receiving taxane-based chemotherapy were enrolled in this two-center study, comprising a training cohort of 243 patients and an external validation cohort of 112 patients. Least absolute shrinkage and selection operator (LASSO) regression and multivariable logistic regression were used to identify independent predictors and develop a nomogram. Model performance was evaluated in terms of discrimination, as measured by the area under the receiver operating characteristic curve (AUC), calibration, assessed using the Brier score, and clinical utility, evaluated by decision curve analysis (DCA). Five independent predictors were identified: history of diabetes, exercise habits, taxane type, body mass index, and age. The nomogram demonstrated good discriminatory performance, with AUCs of 0.835 (95% CI: 0.777–0.887) in the training cohort and 0.832 (95% CI: 0.741–0.911) in the external validation cohort. Calibration was satisfactory, with a Brier score of 0.146 and a calibration slope of 0.95, while DCA demonstrated the model's potential clinical utility. In conclusion, this nomogram provides an effective tool for predicting moderate-to-severe CIPN in patients with breast cancer receiving taxane-based chemotherapy, facilitating early risk stratification and informing personalized prevention and management strategies.
No takes yet. Share an insight, caveat, or question.
Duan et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: